Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02252887
Title Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Gemcitabine + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford Connecticut 06102 United States Details
Memorial Sloan Kettering at Basking Ridge Basking Ridge New Jersey 07920 United States Details
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Westchester Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field